SEARCH:   Advanced

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Keller, S. A. Articles by Cesarman, E. Search for Related Content PubMed PubMed Citation Articles by Keller, S. A. Articles by Cesarman, E. Related Collections Neoplasia Apoptosis Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 1 October 2000, Vol. 96, No. 7, pp. 2537-2542 NEOPLASIA Inhibition of NF-B induces apoptosis of KSHV-infected primary effusion lymphoma cells Shannon A. Keller, Elaine J. Schattner, and Ethel Cesarman From the Weill Graduate School of Medical Sciences of Cornell University, and the Departments of Medicine and Pathology of Weill Medical College of Cornell University, New York, NY.     Abstract Top Abstract Introduction Materials and methods Results Discussion References Kaposi sarcoma-associated herpesvirus (KSHV), or human herpervirus 8 (HHV-8), is a -herpesvirus that infects human lymphocytes and is associated with primary effusion lymphoma (PEL). Currently, the role of viral infection in the transformation of PEL cells is unknown. One possibility is that KSHV, like the lymphotropic viruses Epstein-Barr virus (EBV) and human T-cell leukemia virus I (HTLV-I), activates the transcription factor NF-B to promote survival and proliferation of infected lymphocytes. To examine this possibility, we assessed NF-B activity in KSHV-infected PEL cell lines and primary tumor specimens by electrophoretic mobility shift assay (EMSA). We observed that NF-B is constitutively activated in all KSHV-infected lymphomas, and consists of 2 predominant complexes, p65/p50 heterodimers and p50/p50 homodimers. Inhibition experiments demonstrated that Bay 11-7082, an irreversible inhibitor of IB phosphorylation, completely and specifically abrogated the NF-B/DNA binding in PEL cells. PEL cells treated with Bay 11 demonstrated down-regulation of the NF-B inducible cytokine interleukin 6 (IL-6), and apoptosis. These results suggest that NF-B activity is necessary for survival of KSHV-infected lymphoma cells, and that pharmacologic inhibition of NF-B may be an effective treatment for PEL. (Blood. 2000;96:2537-2542) © 2000 by The American Society of Hematology.     Introduction Top Abstract Introduction Materials and methods Results Discussion References Primary effusion lymphoma (PEL) is a rare, distinct subtype of non-Hodgkin's lymphoma (NHL) that usually presents as lymphomatous effusions in body cavities.1,2 The neoplastic cells have a B-cell genotype, but lack surface expression of some B-cell-associated antigens and surface immunoglobulin. Many of the translocations and mutations associated with other B-cell malignancies are absent in these lymphomas, although the presence of mutations in the regulatory region of bcl-6 has been reported in a subset of cases.3,4 The most unique characteristic of these cells is their consistent infection with Kaposi sarcoma-associated herpesvirus (KSHV), also called human herpesvirus-8 (HHV-8).5 KSHV, a -herpesvirus, can infect multiple cell types, including B cells, which can provide a reservoir for latent virus.6-9 These and other circulating mononuclear cells carrying KSHV are thought to be responsible for viral dissemination, leading to infection of endothelial cells and development of Kaposi sarcoma.10-12 The consistent presence of KSHV in PEL suggests that infection with this virus may contribute to transformation of infected B cells. Like the other lymphomagenic viruses in humans, EBV and HTLV-1, KSHV encodes proteins that modulate and enhance the proliferation and survival of infected cells. Through expression of the viral transforming genes LMP-1 and Tax respectively, EBV and HTLV-1 subvert cellular signaling pathways to activate cellular transcription factors.13-18 Of these, NF-B, a potent inducer of genes involved in the proliferative and survival responses of lymphocytes, is consistently activated and therefore may play an essential role in the transformation process.19-24 This transcription factor occurs as a dimer of rel family proteins that are maintained in an inactive form in the cytoplasm, and that, on activation, translocate to the nucleus and up-regulate gene expression. Among the NF-B target genes are inflammatory cytokines, antiapoptotic proteins, and cell cycle regulators that promote cellular longevity.25-27 To evaluate the NF-B activity in KSHV-infected PEL cells, we have examined 5 cell lines and 2 ex vivo PEL primary clinical specimens. All the cell lines and patient specimens demonstrated constitutive NF-B activity comprised of identical NF-B/rel protein dimers. The application of NF-B inhibitors to the PEL cells resulted in decreased viability. These data suggest that KSHV infection leads to constitutive activation of NF-B, which induces genes vital for the survival and perpetuation of PEL cells.     Materials and methods Top Abstract Introduction Materials and methods Results Discussion References Cell lines and patient specimens The PEL cell lines BC1, BC2, BC4, and BC5 infected with both KSHV and EBV, and BC3 infected with KSHV but not EBV, were maintained in culture with RPMI 1640 (Gibco BRL, Grand Island, NY), supplemented with 20% heat-inactivated fetal bovine serum (FBS) (Gibco) and 50 mg/mL gentamicin (Sigma, St Louis, MO) at 37°C in 5% CO2. The B lymphoma cell line BJAB (KSHV/EBV) was maintained in RPMI supplemented with 10% FBS and gentamicin. For initial experiments involving a direct comparison of NF-B activity between PEL and BJAB cells, all cells were cultured in RPMI with 10% FBS. The clinical pathology specimens were obtained from lymphomatous pleural effusions of 2 human immunodeficiency virus-positive (HIV+) patients. Mononuclear cells were isolated from the pleural fluid by Ficoll-Hypaque (Pharmacia, Piscataway, NJ) density gradient centrifugation, and cryopreserved using standard techniques. Electrophoretic mobility shift assays and supershift analyses For isolation of nuclear proteins, 5 × 106 cells from culture were washed in cold phosphate-buffered saline (PBS) before addition of 400 µL cold buffer A (10 mmol/L HEPES [pH 7.9], 10 mmol/L KCl, 0.1 mmol/L EDTA, 0.1 mmol/L EGTA, 2 µmol/L aprotinin, 2 µmol/L leupeptin, 2 µmol/L pepstatin A, 1 mmol/L DTT, 1 mmol/L PMSF, and 1 mmol/L Na3VO4). After a 15-minute incubation on ice, 25 µL of 10% Nonidet P-40 was added and samples vortexed vigourously. Nuclei were pelleted by centrifugation, washed once in buffer A, and repelleted before the addition of 50 µL buffer B (20 mmol/L HEPES [pH 7.9], 0.4 mol/L NaCl, 10 mmol/L KCl, 0.1 mmol/L EDTA, 0.1 mmol/L EGTA, 2 µmol/L aprotinin, 2 µmol/L leupeptin, 2 µmol/L pepstatin A, 1 mmol/L DTT, 1 mmol/L PMSF, and 1 mmol/L Na3VO4). Nuclear extracts were collected after a 30-minute incubation on ice and subsequent 5-minute centrifugation. Protein was quantitated using a protein bioassay (Bio-Rad, Hercules, CA) with bovine serum albumin standard. For electrophoretic mobility shift assays (EMSAs), NF-B (a gift from Dr Hsiou-Chi Liou, Cornell Medical College, NY), or Oct-1 (Promega, Madison, WI), specific oligonucleotides were end-labeled with T4 kinase and [-32P]ATP. Unincorporated ATP was removed with G-25 sephadex columns and centrifugation. Before addition of oligonucleotide probe, 4 µg of nuclear proteins were incubated with DNA binding mix (2 µg poly (dI-dC), 0.25% NP-40, 5% glycerol, 10 mmol/L Tris HCl, 50 mmol/L KCl, 1 mmol/L DTT, and 1 mmol/L EDTA) for 10 minutes at room temperature. 2 × 104 cpm of radiolabeled oligonucleotide were incubated with the reaction mixture for 15 minutes at room temperature. For cold competition experiments, 50-fold molar excess of either unlabeled Oct-1 or NF-B oligonucleotides were added before the addition of labeled probe. Samples were separated on 7% acrylamide gels and assessed by autoradiography. For supershift experiments, nuclear proteins were incubated with human p65, p50, and c-rel antibodies (Santa Cruz Biotechnology, Santa Cruz, CA) for 30 minutes on ice prior to addition of radiolabeled oligonucleotide and gel electrophoresis were subsequently performed, as described above. Inhibition of NF-B BC3 cells were placed in culture at 5 × 105 cells/mL and screened for inhibition of NF-B after exposure to NF-B inhibitors, obtained from Calbiochem (San Diego, CA), as follows: SN50 (0, 50, and 100 µg/mL), CAPE (0, 20, 40, and 80 mg/mL), aspirin (0, 2, 5, and 10 µmol/L), sodium salicylate (0, 2, 5, and 10 µmol/L), and Bay 11-7082 (0, 2, 4, 5, and 10 µmol/L) for 1 and 24 hours at 37°C. Concentration ranges were selected according to previous reports for effective doses of each inhibitor.28-32 Nuclear proteins were extracted as described above, and EMSAs performed using the NF-B-specific oligonucleotide probe. For specificity experiments, nuclear proteins were extracted from 5 × 106 cells after 1 and 24 hours treatment with Bay 11 and evaluated by EMSA using NF-B and Oct-1 radiolabeled oligonucleotides. For IL-6 assays, 200 µL of triplicate culture supernatants were used for human IL-6 enzyme-linked immunosorbent assays (ELISAs) (University of Maryland Cytokine Core Facility). Immunoblot analyses Whole cell extracts were generated from 5 × 106 BC1, BC2, and BC3 cells treated with or without Bay 11 for 24 hours. Cells were washed once in PBS, followed by lysis in 500 µL of extraction buffer (50 mmol/L Tris-HCl, 1% NP-40, 0.25% sodium deoxycholate, 150 mmol/L NaCl, 1 mmol/L EDTA, 1 mmol/L PMSF, 0.5 µg aprotinin, 0.5 µg leupeptin, 1 mmol/L Na3VO4, 1 mmol/L NaF) for 15 minutes at 4°C. Proteins were quantitated as described above and 30 µg of extract was mixed with 4X sample buffer, boiled for 5 minutes, and loaded on a 12.5% acrylamide gel. Membranes were first probed with phospho-specific p38 antibody (New England Biolabs, Beverly, MA) at 1:1000 dilution in 5% BSA in TBS with 0.1% Tween, overnight at 4°C. Detection was performed using HRP-conjugated rabbit Ig (Amersham, Piscataway, NJ) and chemiluminescence (Amersham). Blots were then stripped and reprobed with p38 antibody (Santa Cruz Biotechnology, Santa Cruz, CA) at 1:1000 dilution in 1% milk in TBS for 1 hour at room temperature. Detection was repeated as described for phopho-p38. Cell viability assays For all assays, 2 × 105 cells were washed once in cold PBS before staining. Morphologic changes associated with apoptosis were evaluated with 4'-6'-diamino-2'-phenylindole dihydrochloride (DAPI, 1 mg/mL) (Sigma, St Louis, MO), and fluorescence microscopy (Axioplan 2, Zeiss). For annexin V binding assays, 5 µL of FITC-conjugated annexin V (Coulter-Immunotech, Miami, FL) in 200 µL binding buffer was added to the cells for 10 minutes at 4°C, and analyzed with a FACSCaliber using CellQuest software (Becton Dickinson, Franklin Lakes, NJ). The viability of cell populations was measured directly by hemocytometry and trypan blue exclusion.     Results Top Abstract Introduction Materials and methods Results Discussion References Constitutive activation of NF-B in KSHV-infected primary effusion lymphoma cells NF-B activity was evaluated by EMSA in the KSHV-infected PEL derived cell lines BC1, BC2, and BC3. As shown in Figure 1A, all 3 PEL cell lines demonstrate significantly greater NF-B/DNA binding, compared to the uninfected B lymphoma cell line BJAB, although the degree of activity varied among the 3 lines evaluated. In all cases, protein/DNA binding was specific for NF-B, as excess unlabeled NF-B oligonucleotide could effectively compete and abrogate binding, whereas unlabeled Oct-1 oligonucleotide demonstrated no effect. Analyses of 2 additional KSHV-infected PEL cell lines BC4 (not shown) and BC5 (Figure 1B), recently established in our laboratory, also showed significant NF-B activity. Overall, these results indicate that there is constitutive activation of the transcription factor in latently infected PEL cells. To determine that the observed NF-B activity was not the result of cell culture, nuclear material from primary ex vivo PEL specimens was assessed by EMSA (Figure 1B). The 2 PEL specimens shown were obtained from KSHV-infected patients, and analyzed without culture. Both samples demonstrated greater NF-B activity, compared with BJAB, and in one case, more activity was observed in the primary tumor cells (PEL specimen 2) than in the cell line that was subsequently established from this clinical specimen (BC5). This suggests that constitutive activation of NF-B is an inherent property of KSHV-infected PEL cells, and not an artifact of culture. View larger version (63K): [in this window] [in a new window]   Figure 1. NF-B is constitutively activated in KSHV-infected PEL cell lines and patient specimens. (A), Nuclear proteins extracted from latent cultures of BC1, BC2, and BC3 cells were examined by EMSA for DNA binding using a radiolabeled NF-B-specific probe. All 3 PEL cell lines demonstrated protein/DNA binding with 2 distinct complex formations, compared with the uninfected negative control cell line BJAB. Cold competition using 50-fold molar excess of unlabeled NF-B and Oct-1 oligonucleotides demonstrated the specificity of the protein/DNA binding complexes. (B), NF-B activity in ex vivo KSHV-infected PEL cells was assessed by EMSA. Mononuclear cells were purified from 2 different patient effusions specimens, and the nuclear proteins were extracted and assessed for NF-B/DNA binding. In one case, the amount of binding in the ex vivo specimen surpassed that of the BC5 cell line subsequently established from the same specimen. BJAB was used as the negative control for NF-B activity. To determine the specific components of these NF-B/DNA complexes, supershift experiments were performed whereby the nuclear proteins were incubated with antibodies to specific rel family proteins before performing EMSAs. These studies (Figure 2) demonstrate identical shifting patterns in the 3 PEL cell lines. As shown, addition of p50 antibody resulted in the complete shift of the lower and a significant portion of the upper complexes, whereas antibody to rel A (p65) affected part of the upper complexes. In the same lysates, antibody to c-rel has no effect. On the basis of these analyses, we conclude that the protein/DNA complexes consist of NF-B/rel family proteins bound to DNA with p50/p50 homodimers and p65/p50 heterodimers. Moreover, although the levels of activity varied among the cell lines, the same types of NF-B complexes were present in each sample, suggesting a common source of NF-B activation in the PELs. View larger version (39K): [in this window] [in a new window]   Figure 2. The protein/DNA complexes in KSHV-positive PELs are primarily comprised of p65/p50 heterodimers and p50 homodimers. To assess the components of the protein/DNA complexes, nuclear proteins extracted from latent cultures of BC1, BC2, and BC3 cells were incubated with antibodies to p50, p65, and c-rel before the addition of NF-B-specific radiolabeled oligonucleotide. Compared with control samples in which no antibody was added (lanes 1, 5, and 9) addition of p50 antibody (lanes 2, 6, and 10) resulted in a complete shift of the lower complex and a large proportion of the upper complex in each cell line. Partial shifting of the upper complex was also seen on addition of p65 antibody, but no shifting of either complex was observed after addition of c-rel antibody. Specific inhibition of NF-B in KSHV-infected primary effusion lymphoma cells To determine the importance of constitutive NF-B activity in PEL cell growth and survival, pharmacologic intervention was used for specific inhibition of NF-B in PEL cells. NF-B inhibitors that are currently available function by one of 3 broad mechanisms: inhibiting proteasome mediated degradation of IB, inhibition of IB phosphorylation, or inhibition of translocation of activated NF-B dimers to the nucleus. In general, the most specific inhibitors are those that inhibit IB phosphorylation and NF-B translocation. These compounds abrogate NF-B induction after stimulation by inflammatory cytokines such as tumor necrosis factor (TNF) and interleukin 1 (IL-1).28-32 We therefore focused on a variety of these inhibitors to block the constitutive activity observed in the KSHV-infected PEL cells. For these studies, we used BC3 cells that are infected with only KSHV. The cells were treated with the IB phosphorylation inhibitors aspirin, sodium salicylate, and Bay 11-7082, or with the nuclear translocation inhibitors SN50 and CAPE. These experiments revealed that only Bay 11, an irreversible inhibitor of IB phosphorylation, could inhibit NF-B/DNA binding in BC-3 cells (Figure 3). Studies extended for as long as 24 hours, with or without further addition of inhibitors, provided the same results, suggesting that functional inhibition of constitutive activity in PEL cells occurs only when signaling is irreversibly blocked upstream of NF-B release and translocation to the nucleus. View larger version (44K): [in this window] [in a new window]   Figure 3. Inhibition of constitutive NF-B activity in BC3 cells. BC3 cells placed in culture at 7.5 × 105 cells/mL were treated for 1 hour with the inhibitors SN50 (A), CAPE (B), and Bay 11-7082 (C). Of the inhibitors tested only Bay 11-7082 inhibited NF-B/DNA binding within 1 hour of treatment. Inhibition observed with Bay 11 was dose dependent, with nearly complete inhibition at the 5 and 10 µmol/L concentrations. Additional studies in which cells were analyzed for up to 24 hours after treatment or were treated with the inhibitors SN50 and CAPE every 2 hours for a 6-hour period yielded the same results. To assess the specificity of NF-B inhibition by Bay 11, the BC1, BC2, BC3, and BJAB cells were treated for 24 hours and evaluated for inhibition of NF-B and Oct-1/DNA binding. Cells were treated with 5 µmol/L Bay 11, based on the inhibitory effect observed in BC3 cells treated at this concentration after 1 hour (Figure 3). In the PEL cells, NF-B/DNA binding was inhibited within 1 hour of treatment and maintained throughout the 24 hours assay (Figure 4). BJAB cells, which demonstrated no constitutive NF-B activity in untreated cells, displayed no change in NF-B DNA binding on treatment with Bay 11 (data not shown). In all cells, treatment with 5 µmol/L Bay 11 did not affect the binding of Oct-1 to DNA in the 24-hour assay, suggesting that at this concentration the inhibitory effects of Bay 11 are specific for NF-B. Further studies indicated that this specificity was lost on treatment with higher concentrations of Bay 11 (data not shown). Therefore, we used the 5 µmol/L concentration of Bay 11 in subsequent experiments to evaluate the consequences of NF-B inhibition in PEL cells. View larger version (38K): [in this window] [in a new window]   Figure 4. Specific inhibition of NF-B with Bay 11-7082.  (A), The PEL cells BC1, BC2, BC3, and control BJAB cells were treated with Bay 11 and assessed for NF-B and Oct-1/DNA binding. Cells were placed in culture at 7.5 × 105 cells/mL and treated with 5 µmol/L Bay 11. After 1 hour and 24 hours, nuclear proteins were extracted and EMSAs performed using NF-B- or Oct-1-specific radiolabeled oligonucleotide probes. All PEL cell lines demonstrated inhibition of NF-B/DNA binding within 1 hour of treatment but demonstrated no inhibition of Oct-1/DNA binding. The specificity of the NF-B inhibition was maintained throughout the 24-hour assay in each cell line. (B), The PEL cells BC1, BC2, and BC3 were treated with 5 µmol/L Bay 11 for 24 hours and assessed by immunoblot for total and phosphorylated p38. All cell lines showed the presence of phosphorylated p38, but the levels of p38 activation were not affected by treatment with Bay 11. Bay 11-7082 is an irreversible inhibitor of IB- phosphorylation, but has also been reported to reversibly stimulate activation of the stress activated protein (SAP) kinases p38 and JNK in human umbilical vein endothelial cells (HUVECs).32 Therefore, to determine whether Bay 11 has an effect on SAP kinases in PEL cells, we performed immunoblot analyses using antibodies to p38 that recognize only its active, phosphorylated form. The data in Figure 4B indicate that p38 is present, and that a proportion of the p38 is phosphorylated in all 3 PEL cell lines. Treatment with Bay 11 for 24 hours did not affect the amount of p38 protein, or the amount of phosphorylated p38 in any of the lines, indicating that the effect of Bay 11 is specific to the NF-B pathway. Effect of NF-B inhibition in KSHV-infected primary effusion lymphoma cells on IL-6 production and survival We evaluated levels of IL-6, an NF-B responsive cytokine, in PEL cells. Table 1 indicates the amount of IL-6 detected in the supernatant of each cell line by ELISA. As shown, the IL-6 activity correlated with the levels of NF-B activity observed in the same PEL cells. To evaluate whether IL-6 production by the PEL cells is NF-B dependent, we determined the effect of NF-B inhibition on IL-6 transcription and secretion. PEL cells were treated with Bay 11 for 24 hours, and evaluated by reverse transcriptase-polymerase chain reaction (RT-PCR) and ELISA for IL-6 transcripts and protein (Table 1). After 24 hours, IL-6 produced by the untreated PEL cells was significantly higher than that produced by BJAB cells. Treatment of these cells with Bay 11 resulted in a significant decrease in IL-6 transcription (data not shown) as well as an 81%, 63%, and 95% reduction in IL-6 produced by BC1, BC2, and BC3 cells, respectively.                                View this table: [in this window] [in a new window]   Table 1. Secretion of IL-6 after 24-hour treatment with Bay 11  We also evaluated the effect of NF-B inhibition on PEL cell growth and survival. Compared with BJAB, the KSHV-infected PEL cells demonstrated decreased viability after 24 hours of treatment with Bay 11, as was evident by reduction in cell number and the percentage of viable cells (Figure 5A). In contrast, BJAB cells continued to proliferate after Bay 11 treatment, although their growth rate was slightly decreased compared with that of untreated BJAB cells. To determine whether growth inhibition in the PEL cells treated with Bay 11 was due to induction of apoptosis, cells treated with inhibitor for 24 hours were assessed by annexin V staining and flow cytometry (Figure 5B). PEL cells treated with Bay 11 demonstrated significant apoptosis, compared with untreated cells. Similar results were evident in the treated cells by DAPI staining, which revealed marked nuclear condensation and blebbing (Figure 5C). Taken together, these data suggest that constitutive NF-B activity is vital for survival of KSHV-infected PEL cells, and that specific inhibition of this activity results in the induction of apoptosis. View larger version (40K): [in this window] [in a new window]   Figure 5. Decreased cell viability and the induction of apoptosis in PEL cells treated with Bay 11.  BC1, BC2, BC3, and BJAB cells were placed in culture at 7.5 × 105 cells/mL without Bay 11 or with 5 µmol/L Bay 11 for 24 hours. (A), Cell viability was assessed by hemocytometry and trypan blue exclusion, and is reported as the percentage of viable cells remaining at 24 hours, relative to the initial viable cell number (100%). Data shown are compiled from 5 independent experiments, and are shown for both untreated (continuous line) and treated (dashed line) cells. (B), Induction of apoptosis in PEL cells on inhibition of NF-B. 2 × 105 cells were labeled with FITC-conjugated annexin-V and analyzed by flow cytometry. The percentage of apoptotic cells from 4 independent experiments are reported for both untreated (white bar) and Bay 11 treated (black bar) cells. (C), DAPI staining of BC3 cells with or without treatment with 5 µmol/L Bay 11 for 24 hours shows significant nuclear condensation and fragmentation in the treated cells.     Discussion Top Abstract Introduction Materials and methods Results Discussion References In this study, we have found that the transcription factor NF-B is constitutively activated in KSHV-infected PEL cells. This finding suggests that like EBV and HTLV-1, KSHV infection of lymphocytes can lead to activation of NF-B. Our data indicate that activation of NF-B is essential for the survival of KSHV-infected lymphomas, as inhibition of this transcription factor results in apoptosis of PEL cells. Whereas the transforming proteins of EBV and HTLV-1, LMP-1 and Tax, respectively, are able to activate NF-B, the molecular source of this activity in PEL remains to be elucidated. Although most PELs are dually infected with KSHV and EBV, the latter virus is unlikely to be involved in the activation of NF-B in these cells, as PELs have a restricted EBV latency pattern with minimal LMP-1 expression.33,34 To eliminate the possibility of confounding results due to EBV involvement in the activation of NF-B, we evaluated PEL cells infected only with KSHV (BC3), as well as cells dually infected with KSHV and EBV (BC1 and BC2). It has been reported that the KSHV-encoded proteins K1, a viral signaling receptor, and FLICE inhibitory protein (vFLIP) can activate NF-B when overexpressed in some mammalian, albeit nonlymphoid, cell types.35,36 Preliminary studies in our laboratory have also suggested that the KSHV-encoded G-protein coupled receptor (GPCR) has NF-B activating potential (unpublished observation). These findings suggest that in lymphocytes, expression of one or more KSHV-encoded gene products results in the constitutive activity that we have observed. Although this activation may be a direct effect of signaling cascades initiated by viral receptors such as K1 and GPCR,37,38 it could occur indirectly due to modulation of cellular signaling pathways. The KSHV-encoded FLIP, which modulates signaling of the TNF superfamily receptors, could enhance survival of PEL cells via activation of NF-B and inhibition of apoptotic pathways. As the PEL cells, which have aberrant expression of many surface receptors, express TNFRI (p55) and TNFRII (p75), the possibility of receptor activation and modulation, perhaps through an autocrine or paracrine loop, remains to be explored. An important observation to emerge from this study is that the NF-B activity in PEL cells can be inhibited specifically by the compound Bay 11-7082. Inhibition of NF-B in PEL cells occurs at concentrations that do not affect binding of other transcription factors or activation of the SAP kinase p38. Previous studies have examined the ability of various compounds to inhibit inducible activation of NF-B, but not constitutive activity, in transformed cells.28-32 Using a variety of inhibitors, we have found that inhibition of NF-B only occurred in PEL cells when IB was stabilized by inhibition of phosphorylation, such that degradation of IB no longer occurs. These findings suggest that in cells in which NF-B is constitutively activated, inhibition must be upstream of activated dimer release and translocation. The data indicate that activity can be inhibited in cells with constitutive NF-B activity, even when the source of activation is unknown. In PEL cells the abundance of activated complexes are p65/p50 heterodimers that have potent transcriptional regulatory capabilities in lymphocytes.39-41 Therefore, it is likely that constitutive activation of these complexes results in up-regulation of genes important for cell growth and survival. Here we show that IL-6, an NF-B-inducible cytokine, is produced at levels proportional to the NF-B activity observed in the PEL cells and that inhibition of NF-B results in a significant decrease of IL-6 secretion by these cells. Because IL-6 enhances B cell proliferation,42-45 down-regulation of IL-6 may be a factor in reduced PEL cell growth. In summary, we have found that NF-B is a constitutively activated transcription factor that is involved in survival of KSHV-infected PEL cells, as NF-B inhibition results in induction of apoptosis. This finding suggests that NF-B is important for PEL survival, and also suggests a new possible target for the treatment of PEL. In our experience with these highly aggressive malignancies, the mean survival of patients is extremely poor even with aggressive chemotherapeutic intervention. Therefore, the possibility of inhibiting NF-B, which might sensitize the cells to subsequent apoptosic stimuli, is a promising novel therapeutic approach.     Acknowledgments We thank Dr Daniel Knowles and Dr Amy Chadburn for providing and characterizing the primary patient specimens. We are also grateful to Denise Hernandez-Hopkins and Zahra Asgary for excellent technical assistance.     Footnotes Submitted March 7, 2000; accepted June 1, 2000. Supported in part by National Institutes of Health grants CA73531, CA82037, and CA68939 to E.C. The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734. Reprints: Ethel Cesarman, Department of Pathology, Weill Medical College of Cornell University, 1300 York Ave, New York, NY 10021; e-mail: ecesarm{at}mail.med.cornell.edu.     References Top Abstract Introduction Materials and methods Results Discussion References 1. Knowles DM, Inghirami G, Ubriaco A, Dalla-Favera R. Molecular genetic analysis of three AIDS-associated neoplasms of uncertain lineage demonstrates their B-cell derivation and the possible pathogenetic role of the Epstein-Barr virus. Blood. 1989;73:792-799[Abstract/Free Full Text]. 2. Walts AE, Shintaku IP, Said JW. Diagnosis of malignant lymphoma in effusions from patients with AIDS by gene rearrangement. Am J Clin Path. 1990;94:170-175[Medline] [Order article via Infotrieve]. 3. Nador RG, Cesarman E, Chadburn A, et al. Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpesvirus. Blood. 1996;88:645-656[Abstract/Free Full Text]. 4. Gaidano G, Gloghini A, Gattei V, et al. Association of Kaposi's sarcoma-associated herpesvirus-positive primary effusion lymphoma with expression of the CD138/syndecan-1 antigen. Blood. 1997;90:4894-4900[Abstract/Free Full Text]. 5. Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body cavity-based lymphomas. N Eng J Med. 1995;332:1186-1191[Abstract/Free Full Text]. 6. Mesri EA, Cesarman E, Arvanitakis L, et al. Human herpesvirus-8/Kaposi's sarcoma-associated herpesvirus is a new transmissible virus that infects B cells. J Exp Med. 1996;183:2385-2390[Abstract/Free Full Text]. 7. Foreman KE, Friborg J Jr, Kong WP, et al. Propagation of a human herpesvirus from AIDS-associated Kaposi's sarcoma. N Engl J Med. 1997;336:163-171[Abstract/Free Full Text]. 8. Staskus KA, Zhong W, Gebhard K, et al. Kaposi's sarcoma-associated herpesvirus gene expression in endothelial (spindle) tumor cells. J Virol. 1997;71:715-719[Abstract]. 9. Flore O, Rafii S, Ely S, O'Leary JJ, Hyjek EM, Cesarman E. Transformation of primary human endothelial cells by Kaposi's sarcoma-associated herpesvirus. Nature. 1998;394:588-592[Medline] [Order article via Infotrieve]. 10. Harrington WJ Jr, Bagasra O, Sosa CE, et al. Human herpesvirus type 8 DNA sequences in cell-free plasma and mononuclear cells of Kaposi's sarcoma patients. J Infect Dis. 1996;174:1101-1105[Medline] [Order article via Infotrieve]. 11. Sirianni MC, Vincenzi L, Fiorelli V, et al. gamma-Interferon production in peripheral blood mononuclear cells and tumor infiltrating lymphocytes from Kaposi's sarcoma patients: correlation with the presence of human herpesvirus-8 in peripheral blood mononuclear cells and lesional macrophages. Blood. 1998;91:968-976[Abstract/Free Full Text]. 12. Monini P, Colombini S, Sturzl M, et al. Reactivation and persistence of human herpesvirus-8 infection in B cells and monocytes by Th-1 cytokines increased in Kaposi's sarcoma. Blood. 1999;93:4044-4058[Abstract/Free Full Text]. 13. Wang D, Liebowitz D, Kieff E. An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell. 1985;43:831-840[Medline] [Order article via Infotrieve]. 14. Izumi KM, Kieff ED. The Epstein-Barr virus oncogene product latent membrane protein 1 engages the tumor necrosis factor receptor-associated death domain to mediate B lymphocyte growth transformation and activate NF-B. Proc Natl Acad Sci U S A. 1997;94:12592-12597[Abstract/Free Full Text]. 15. Liebowitz D. Epstein-Barr virus and a cellular signaling pathway in lymphomas from immunosuppressed patients. N Engl J Med. 1998;338:1413-1421[Abstract/Free Full Text]. 16. Kaye KM, Devergne O, Harada JN, et al. Tumor necrosis factor receptor associated factor 2 is a mediator of NF-kappa B activation by latent infection membrane protein 1, the Epstein-Barr virus transforming protein. Proc Natl Acad Sci U S A. 1996;93:11085-11090[Abstract/Free Full Text]. 17. Ruben S, Poteat H, Tan T, et al. Cellular transcription factors and regulation of IL-2 receptor gene expression by HTLV-I tax gene product. Science. 1988;241:89-92[Abstract/Free Full Text]. 18. Leung K, Nabel GJ. HTLV-1 transactivator induces interleukin-2 receptor expression through an NF-kappa B-like factor. Nature. 1988;333:776-778[Medline] [Order article via Infotrieve]. 19. Izumi KM, McFarland EC, Ting AT, Riley EA, Seed B, Kieff ED. The Epstein-Barr virus oncoprotein latent membrane protein 1 engages the tumor necrosis factor receptor-associated proteins TRADD and receptor-interacting protein (RIP) but does not induce apoptosis or require RIP for NF-kappaB activation. Mol Cell Biol. 1999;19:5759-5767[Abstract/Free Full Text]. 20. Kaye KM, Izumi KM, Li H, et al. An Epstein-Barr virus that expresses only the first 231 LMP1 amino acids efficiently initiates primary Blymphocyte growth transformation. J Virol. 1999;73:10525-10530[Abstract/Free Full Text]. 21. Devergne O, Hatzivassiliou E, Izumi KM, et al. Association of TRAF1, TRAF2, and TRAF3 with an Epstein-Barr virus LMP1 domain important for B-lymphocyte transformation: Role in NF-kappa B activation. Mol Cell Biol. 1996;16:7098-7108[Abstract]. 22. Geleziunas R, Ferrell S, Lin X, et al. Human T-cell leukemia virus type 1 Tax induction of NF-kappaB involves activation of the IkappaB kinase alpha (IKKalpha) and IKKbeta cellular kinases. Mol Cell Biol. 1998;18:5157-5165[Abstract/Free Full Text]. 23. Coscoy L, Gonzalez-Dunia D, Tangy F, Syan S, Brahic M, Ozden S. Molecular mechanism of tumorigenesis in mice transgenic for the human T cell leukemia virus Tax gene. Virology. 1998;248:332-341[Medline] [Order article via Infotrieve]. 24. Mori N, Fuji M, Ikeda S, et al. Constitutive activation of NF-kappaB in primary adult T-cell leukemia cells. Blood. 1999;93:2360-2368[Abstract/Free Full Text]. 25. Gerondakis S, Grumont R, Rourke I, Grossman M. The regulation and roles of Rel/NF-B transcription factors during lymphocyte activation. Curr Opin Immunol. 1998;10:353-359[Medline] [Order article via Infotrieve]. 26. Ghosh S, May MJ, Kopp EB. NF-B and REL proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol. 1998;16:225-260[Medline] [Order article via Infotrieve]. 27. Grumont RJ, Rourke IJ, O'Reilly LA, et al. B lymphocytes differentially use the Rel and nuclear factor kappaB1 (NF- kappaB1) transcription factors to regulate cell cycle progression and apoptosis in quiescent and mitogen-activated cells. J Exp Med. 1998;187:663-674[Abstract/Free Full Text]. 28. Yin MJ, Yamamoto Y, Gaynor RB. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature. 1998;396:77-80[Medline] [Order article via Infotrieve]. 29. Kopp E, Ghosh S. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science. 1994;265:956-959[Abstract/Free Full Text]. 30. Natarajan K, Singh S, Burke TR, Grunberger D, Aggarwal BB. Caffeic acid phenethyl ester is a potent and specific inhibitor of activation of nuclear transcription factor NF-kappa B. Proc Natl Acad Sci U S A. 1996;93:9090-9095[Abstract/Free Full Text]. 31. Lin YZ, Yao SY, Veach RA, Torgerson TR, Hawiger J. Inhibition of nuclear translocation of transcription factor NF-kappa B by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence. J Biol Chem. 1995;270:14255-14258[Abstract/Free Full Text]. 32. Pierce JW, Schoenleber R, Jesmok G, et al. Novel inhibitors of cytokine-induced IkappaBalpha phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo. J Biol Chem. 1997;272:21096-21103[Abstract/Free Full Text]. 33. Horenstein MG, Nador RG, Chadburn A, et al. Epstein-Barr virus latent gene expression in primary effusion lymphomas containing Kaposi's sarcoma-associated herpesvirus human herpesvirus-8. Blood. 1997;90:1186-1191[Abstract/Free Full Text]. 34. Szekely L, Chen F, Teramoto N, et al. Restricted expression of Epstein-Barr virus (EBV)-encoded, growth transformation-associated antigens in an EBV- and human herpesvirus type 8-carrying body cavity lymphoma line. Gen Virol. 1998;79:1445-1452[Abstract]. 35. Samaniego F, Pati S, Prakash O, Bose D. K1 associated nuclear factor-kappa B-dependent promoter activity: a role in Kaposi's sarcoma inflammation? J Natl Cancer Inst. In Press. 36. Chaudary PM, Jasmin A, Eby MT, Hood L. modulation of the NF-kappa B pathway by virally encoded death effector domains-containing proteins. Oncogene. 1999;18:5738-5748[Medline] [Order article via Infotrieve]. 37. Lee H, Guo J, Li M, et al. Identification of an immunoreceptor tyrosine-based activation motif of K1 transforming protein of Kaposi's sarcoma-associated herpesvirus. Mol Cell Biol. 1998;18:5219-5228[Abstract/Free Full Text]. 38. Bais C, Santomasso B, Coso O, et al. G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator. Nature. 1998;391:86-89[Medline] [Order article via Infotrieve]. 39. Karin M. The NF-kappa B activation pathway: its regulation and role in inflammation and cell survival. Cancer J Sci Am. 1998;4(Suppl 1):S92-99. 40. Lee HH, Dadgostar H, Cheng Q, Shu J, Cheng G. NF-kappaB-mediated up-regulation of Bcl-x and Bfl-1/A1 is required for CD40 survival signaling in B lymphocytes. Proc Natl Acad Sci U S A. 1999;96:9136-9141[Abstract/Free Full Text]. 41. Luque I, Gelinas C. Rel/NF-kappa B and I kappa B factors in oncogenesis. Semin Cancer Biol. 1997;8:103-111[Medline] [Order article via Infotrieve]. 42. Kato H, Kinoshita T, Suzuki S, et al. Production and effects of interleukin-6 and other cytokines in patients with non-Hodgkin's lymphoma. Leuk Lymphoma. 1998;29:71-79[Medline] [Order article via Infotrieve]. 43. Dolcetti R, Boiocchi M. Cellular and molecular bases of B-cell clonal expansions. Clin Exp Rheumatol. 1996;14:S3-13. 44. Rieckmann P, Tuscano JM, Kehrl JH. Tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) in B-lymphocyte function. Methods. 1997;11:128-132[Medline] [Order article via Infotrieve]. 45. Drexler HG, Meyer C, Gaidano G, Carbone A. Constitutive cytokine production by primary effusion (body cavity-based) lymphoma-derived cell lines. Leukemia. 1999;13:634-640[Medline] [Order article via Infotrieve]. © 2000 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: J. Duchene, C. Cayla, S. Vessillier, R. Scotland, K. Yamashiro, F. Lecomte, I. Syed, P. Vo, A. Marrelli, C. Pitzalis, et al. Laminar Shear Stress Regulates Endothelial Kinin B1 Receptor Expression and Function: Potential Implication in Atherogenesis Arterioscler Thromb Vasc Biol, November 1, 2009; 29(11): 1757 - 1763. [Abstract] [Full Text] [PDF] M. Karin NF-{kappa}B as a Critical Link Between Inflammation and Cancer Cold Spring Harb Perspect Biol, November 1, 2009; 1(5): a000141 - a000141. [Abstract] [Full Text] [PDF] M.-O. Kim, D.-O. Moon, J. M. Jung, W. S. Lee, Y. H. Choi, and G.-Y. Kim Agaricus blazei Extract Induces Apoptosis through ROS-dependent JNK Activation Involving the Mitochondrial Pathway and Suppression of Constitutive NF-{kappa}B in THP-1 Cells Evid. Based Complement. Altern. Med., October 27, 2009; (2009) nep176v1. [Abstract] [Full Text] [PDF] F. Gould, S. M. Harrison, E. W. Hewitt, and A. Whitehouse Kaposi's Sarcoma-Associated Herpesvirus RTA Promotes Degradation of the Hey1 Repressor Protein through the Ubiquitin Proteasome Pathway J. Virol., July 1, 2009; 83(13): 6727 - 6738. [Abstract] [Full Text] [PDF] V. Punj, H. Matta, S. Schamus, T. Yang, Y. Chang, and P. M. Chaudhary Induction of CCL20 production by Kaposi sarcoma-associated herpesvirus: role of viral FLICE inhibitory protein K13-induced NF-{kappa}B activation Blood, May 28, 2009; 113(22): 5660 - 5668. [Abstract] [Full Text] [PDF] L. T. Krug, C. M. Collins, L. M. Gargano, and S. H. Speck NF-{kappa}B p50 Plays Distinct Roles in the Establishment and Control of Murine Gammaherpesvirus 68 Latency J. Virol., May 15, 2009; 83(10): 4732 - 4748. [Abstract] [Full Text] [PDF] D. L. Di Bartolo, E. Hyjek, S. Keller, I. Guasparri, H. Deng, R. Sun, A. Chadburn, D. M. Knowles, and E. Cesarman Role of Defective Oct-2 and OCA-B Expression in Immunoglobulin Production and Kaposi's Sarcoma-Associated Herpesvirus Lytic Reactivation in Primary Effusion Lymphoma J. Virol., May 1, 2009; 83(9): 4308 - 4315. [Abstract] [Full Text] [PDF] A. Konrad, E. Wies, M. Thurau, G. Marquardt, E. Naschberger, S. Hentschel, R. Jochmann, T. F. Schulz, H. Erfle, B. Brors, et al. A Systems Biology Approach To Identify the Combination Effects of Human Herpesvirus 8 Genes on NF-{kappa}B Activation J. Virol., March 15, 2009; 83(6): 2563 - 2574. [Abstract] [Full Text] [PDF] A. Carbone, E. Cesarman, M. Spina, A. Gloghini, and T. F. Schulz HIV-associated lymphomas and gamma-herpesviruses Blood, February 5, 2009; 113(6): 1213 - 1224. [Abstract] [Full Text] [PDF] D. L. Di Bartolo, M. Cannon, Y.-F. Liu, R. Renne, A. Chadburn, C. Boshoff, and E. Cesarman KSHV LANA inhibits TGF-{beta} signaling through epigenetic silencing of the TGF-{beta} type II receptor Blood, May 1, 2008; 111(9): 4731 - 4740. [Abstract] [Full Text] [PDF] S. Efklidou, R. Bailey, N. Field, M. Noursadeghi, and M. K. Collins vFLIP from KSHV inhibits anoikis of primary endothelial cells J. Cell Sci., February 15, 2008; 121(4): 450 - 457. [Abstract] [Full Text] [PDF] M-Q Du, C M Bacon, and P G Isaacson Kaposi sarcoma-associated herpesvirus/human herpesvirus 8 and lymphoproliferative disorders J. Clin. Pathol., December 1, 2007; 60(12): 1350 - 1357. [Abstract] [Full Text] [PDF] P. Zou, J. Kawada, L. Pesnicak, and J. I. Cohen Bortezomib Induces Apoptosis of Epstein-Barr Virus (EBV)-Transformed B Cells and Prolongs Survival of Mice Inoculated with EBV-Transformed B Cells J. Virol., September 15, 2007; 81(18): 10029 - 10036. [Abstract] [Full Text] [PDF] B. Burke, H. J. Brown, M. D. Marsden, G. Bristol, D. N. Vatakis, and J. A. Zack Primary Cell Model for Activation-Inducible Human Immunodeficiency Virus J. Virol., July 15, 2007; 81(14): 7424 - 7434. [Abstract] [Full Text] [PDF] S. Sadagopan, N. Sharma-Walia, M. V. Veettil, H. Raghu, R. Sivakumar, V. Bottero, and B. Chandran Kaposi's Sarcoma-Associated Herpesvirus Induces Sustained NF-{kappa}B Activation during De Novo Infection of Primary Human Dermal Microvascular Endothelial Cells That Is Essential for Viral Gene Expression J. Virol., April 15, 2007; 81(8): 3949 - 3968. [Abstract] [Full Text] [PDF] P. J. Jost and J. Ruland Aberrant NF-{kappa}B signaling in lymphoma: mechanisms, consequences, and therapeutic implications Blood, April 1, 2007; 109(7): 2700 - 2707. [Abstract] [Full Text] [PDF] E. Caselli, S. Fiorentini, C. Amici, D. Di Luca, A. Caruso, and M. G. Santoro Human herpesvirus 8 acute infection of endothelial cells induces monocyte chemoattractant protein 1-dependent capillary-like structure formation: role of the IKK/NF-{kappa}B pathway Blood, April 1, 2007; 109(7): 2718 - 2726. [Abstract] [Full Text] [PDF] J. C. Ramos, P. Ruiz Jr, L. Ratner, I. M. Reis, C. Brites, C. Pedroso, G. E. Byrne Jr, N. L. Toomey, V. Andela, E. W. Harhaj, et al. IRF-4 and c-Rel expression in antiviral-resistant adult T-cell leukemia/lymphoma Blood, April 1, 2007; 109(7): 3060 - 3068. [Abstract] [Full Text] [PDF] Y. Zeng, X. Zhang, Z. Huang, L. Cheng, S. Yao, D. Qin, X. Chen, Q. Tang, Z. Lv, L. Zhang, et al. Intracellular Tat of Human Immunodeficiency Virus Type 1 Activates Lytic Cycle Replication of Kaposi's Sarcoma-Associated Herpesvirus: Role of JAK/STAT Signaling J. Virol., March 1, 2007; 81(5): 2401 - 2417. [Abstract] [Full Text] [PDF] S. Wang, S. Wang, H. Maeng, D. P. Young, O. Prakash, L. E. Fayad, A. Younes, and F. Samaniego K1 protein of human herpesvirus 8 suppresses lymphoma cell Fas-mediated apoptosis Blood, March 1, 2007; 109(5): 2174 - 2182. [Abstract] [Full Text] [PDF] S. A. R. Rezaee, C. Cunningham, A. J. Davison, and D. J. Blackbourn Kaposi's sarcoma-associated herpesvirus immune modulation: an overview J. Gen. Virol., July 1, 2006; 87(7): 1781 - 1804. [Abstract] [Full Text] [PDF] M. Arguello, S. Paz, E. Hernandez, C. Corriveau-Bourque, L. M. Fawaz, J. Hiscott, and R. Lin Leukotriene A4 Hydrolase Expression in PEL Cells Is Regulated at the Transcriptional Level and Leads to Increased Leukotriene B4 Production. J. Immunol., June 1, 2006; 176(11): 7051 - 7061. [Abstract] [Full Text] [PDF] S. A. Keller, D. Hernandez-Hopkins, J. Vider, V. Ponomarev, E. Hyjek, E. J. Schattner, and E. Cesarman NF-{kappa}B is essential for the progression of KSHV- and EBV-infected lymphomas in vivo Blood, April 15, 2006; 107(8): 3295 - 3302. [Abstract] [Full Text] [PDF] J. Yang, K. I. Amiri, J. R. Burke, J. A. Schmid, and A. Richmond BMS-345541 Targets Inhibitor of {kappa}B Kinase and Induces Apoptosis in Melanoma: Involvement of Nuclear Factor {kappa}B and Mitochondria Pathways Clin. Cancer Res., February 1, 2006; 12(3): 950 - 960. [Abstract] [Full Text] [PDF] M. Watanabe, T. Ohsugi, M. Shoda, T. Ishida, S. Aizawa, M. Maruyama-Nagai, A. Utsunomiya, S. Koga, Y. Yamada, S. Kamihira, et al. Dual targeting of transformed and untransformed HTLV-1-infected T cells by DHMEQ, a potent and selective inhibitor of NF-{kappa}B, as a strategy for chemoprevention and therapy of adult T-cell leukemia Blood, October 1, 2005; 106(7): 2462 - 2471. [Abstract] [Full Text] [PDF] P. Chugh, H. Matta, S. Schamus, S. Zachariah, A. Kumar, J. A. Richardson, A. L. Smith, and P. M. Chaudhary Constitutive NF-{kappa}B activation, normal Fas-induced apoptosis, and increased incidence of lymphoma in human herpes virus 8 K13 transgenic mice PNAS, September 6, 2005; 102(36): 12885 - 12890. [Abstract] [Full Text] [PDF] M. Kurokawa, S. K. Ghosh, J. C. Ramos, A. M. Mian, N. L. Toomey, L. Cabral, D. Whitby, G. N. Barber, D. P. Dittmer, and W. J. Harrington Jr Azidothymidine inhibits NF-{kappa}B and induces Epstein-Barr virus gene expression in Burkitt lymphoma Blood, July 1, 2005; 106(1): 235 - 240. [Abstract] [Full Text] [PDF] O. Prakash, O. R. Swamy, X. Peng, Z.-Y. Tang, L. Li, J. E. Larson, J. C. Cohen, J. Gill, G. Farr, S. Wang, et al. Activation of Src kinase Lyn by the Kaposi sarcoma-associated herpesvirus K1 protein: implications for lymphomagenesis Blood, May 15, 2005; 105(10): 3987 - 3994. [Abstract] [Full Text] [PDF] A. Godfrey, J. Anderson, A. Papanastasiou, Y. Takeuchi, and C. Boshoff Inhibiting primary effusion lymphoma by lentiviral vectors encoding short hairpin RNA Blood, March 15, 2005; 105(6): 2510 - 2518. [Abstract] [Full Text] [PDF] A. R. Jazirehi, S. Huerta-Yepez, G. Cheng, and B. Bonavida Rituximab (Chimeric Anti-CD20 Monoclonal Antibody) Inhibits the Constitutive Nuclear Factor-{kappa}B Signaling Pathway in Non-Hodgkin's Lymphoma B-Cell Lines: Role in Sensitization to Chemotherapeutic Drug-induced Apoptosis Cancer Res., January 1, 2005; 65(1): 264 - 276. [Abstract] [Full Text] [PDF] L. T. Lam, R. E. Davis, J. Pierce, M. Hepperle, Y. Xu, M. Hottelet, Y. Nong, D. Wen, J. Adams, L. Dang, et al. Small Molecule Inhibitors of I{kappa}B Kinase Are Selectively Toxic for Subgroups of Diffuse Large B-Cell Lymphoma Defined by Gene Expression Profiling Clin. Cancer Res., January 1, 2005; 11(1): 28 - 40. [Abstract] [Full Text] [PDF] T. Luft, E. Maraskovsky, M. Schnurr, K. Knebel, M. Kirsch, M. Gorner, R. Skoda, A. D. Ho, P. Nawroth, and A. Bierhaus Tuning the volume of the immune response: strength and persistence of stimulation determine migration and cytokine secretion of dendritic cells Blood, August 15, 2004; 104(4): 1066 - 1074. [Abstract] [Full Text] [PDF] H. Matta and P. M. Chaudhary Activation of alternative NF-{kappa}B pathway by human herpes virus 8-encoded Fas-associated death domain-like IL-1{beta}-converting enzyme inhibitory protein (vFLIP) PNAS, June 22, 2004; 101(25): 9399 - 9404. [Abstract] [Full Text] [PDF] E. D. Cahir-McFarland, K. Carter, A. Rosenwald, J. M. Giltnane, S. E. Henrickson, L. M. Staudt, and E. Kieff Role of NF-{kappa}B in Cell Survival and Transcription of Latent Membrane Protein 1-Expressing or Epstein-Barr Virus Latency III-Infected Cells J. Virol., April 15, 2004; 78(8): 4108 - 4119. [Abstract] [Full Text] [PDF] I. Guasparri, S. A. Keller, and E. Cesarman KSHV vFLIP Is Essential for the Survival of Infected Lymphoma Cells J. Exp. Med., April 5, 2004; 199(7): 993 - 1003. [Abstract] [Full Text] [PDF] Y. Dai, X.-Y. Pei, M. Rahmani, D. H. Conrad, P. Dent, and S. Grant Interruption of the NF-{kappa}B pathway by Bay 11-7082 promotes UCN-01-mediated mitochondrial dysfunction and apoptosis in human multiple myeloma cells Blood, April 1, 2004; 103(7): 2761 - 2770. [Abstract] [Full Text] [PDF] Q. Sun, S. Zachariah, and P. M. Chaudhary The Human Herpes Virus 8-Encoded Viral FLICE-inhibitory Protein Induces Cellular Transformation via NF-{kappa}B Activation J. Biol. Chem., December 26, 2003; 278(52): 52437 - 52445. [Abstract] [Full Text] [PDF] S. Shi, C. Nathan, D. Schnappinger, J. Drenkow, M. Fuortes, E. Block, A. Ding, T. R. Gingeras, G. Schoolnik, S. Akira, et al. MyD88 Primes Macrophages for Full-Scale Activation by Interferon-{gamma} yet Mediates Few Responses to Mycobacterium tuberculosis J. Exp. Med., October 6, 2003; 198(7): 987 - 997. [Abstract] [Full Text] [PDF] N. Field, W. Low, M. Daniels, S. Howell, L. Daviet, C. Boshoff, and M. Collins KSHV vFLIP binds to IKK-{gamma} to activate IKK J. Cell Sci., September 15, 2003; 116(18): 3721 - 3728. [Abstract] [Full Text] [PDF] H. J. Brown, M. J. Song, H. Deng, T.-T. Wu, G. Cheng, and R. Sun NF-{kappa}B Inhibits Gammaherpesvirus Lytic Replication J. Virol., August 1, 2003; 77(15): 8532 - 8540. [Abstract] [Full Text] [PDF] L. A. Dourmishev, A. L. Dourmishev, D. Palmeri, R. A. Schwartz, and D. M. Lukac Molecular Genetics of Kaposi's Sarcoma-Associated Herpesvirus (Human Herpesvirus 8) Epidemiology and Pathogenesis Microbiol. Mol. Biol. Rev., June 1, 2003; 67(2): 175 - 212. [Abstract] [Full Text] [PDF] M. Z. Dewan, K. Terashima, M. Taruishi, H. Hasegawa, M. Ito, Y. Tanaka, N. Mori, T. Sata, Y. Koyanagi, M. Maeda, et al. Rapid Tumor Formation of Human T-Cell Leukemia Virus Type 1-Infected Cell Lines in Novel NOD-SCID/{gamma}cnull Mice: Suppression by an Inhibitor against NF-{kappa}B J. Virol., May 1, 2003; 77(9): 5286 - 5294. [Abstract] [Full Text] [PDF] S. K. Ghosh, C. Wood, L. H. Boise, A. M. Mian, V. V. Deyev, G. Feuer, N. L. Toomey, N. C. Shank, L. Cabral, G. N. Barber, et al. Potentiation of TRAIL-induced apoptosis in primary effusion lymphoma through azidothymidine-mediated inhibition of NF-kappa B Blood, March 15, 2003; 101(6): 2321 - 2327. [Abstract] [Full Text] [PDF] Q. Sun, H. Matta, and P. M. Chaudhary The human herpes virus 8-encoded viral FLICE inhibitory protein protects against growth factor withdrawal-induced apoptosis via NF-kappa B activation Blood, March 1, 2003; 101(5): 1956 - 1961. [Abstract] [Full Text] [PDF] M. Cannon, N. J. Philpott, and E. Cesarman The Kaposi's Sarcoma-Associated Herpesvirus G Protein-Coupled Receptor Has Broad Signaling Effects in Primary Effusion Lymphoma Cells J. Virol., December 6, 2002; 77(1): 57 - 67. [Abstract] [Full Text] [PDF] O. Gutierrez, C. Pipaon, N. Inohara, A. Fontalba, Y. Ogura, F. Prosper, G. Nunez, and J. L. Fernandez-Luna Induction of Nod2 in Myelomonocytic and Intestinal Epithelial Cells via Nuclear Factor-kappa B Activation J. Biol. Chem., October 25, 2002; 277(44): 41701 - 41705. [Abstract] [Full Text] [PDF] N. Mori, Y. Yamada, S. Ikeda, Y. Yamasaki, K. Tsukasaki, Y. Tanaka, M. Tomonaga, N. Yamamoto, and M. Fujii Bay 11-7082 inhibits transcription factor NF-kappa B and induces apoptosis of HTLV-I-infected T-cell lines and primary adult T-cell leukemia cells Blood, August 13, 2002; 100(5): 1828 - 1834. [Abstract] [Full Text] [PDF] O. Prakash, Z.-Y. Tang, X. Peng, R. Coleman, J. Gill, G. Farr, and F. Samaniego Tumorigenesis and Aberrant Signaling in Transgenic Mice Expressing the Human Herpesvirus-8 K1 Gene J Natl Cancer Inst, June 19, 2002; 94(12): 926 - 935. [Abstract] [Full Text] [PDF] T. Hideshima, D. Chauhan, P. Richardson, C. Mitsiades, N. Mitsiades, T. Hayashi, N. Munshi, L. Dang, A. Castro, V. Palombella, et al. NF-kappa B as a Therapeutic Target in Multiple Myeloma J. Biol. Chem., May 3, 2002; 277(19): 16639 - 16647. [Abstract] [Full Text] [PDF] L. Liu, M. T. Eby, N. Rathore, S. K. Sinha, A. Kumar, and P. M. Chaudhary The Human Herpes Virus 8-encoded Viral FLICE Inhibitory Protein Physically Associates with and Persistently Activates the Ikappa B Kinase Complex J. Biol. Chem., April 12, 2002; 277(16): 13745 - 13751. [Abstract] [Full Text] [PDF] T. V. Sharp, H.-W. Wang, A. Koumi, D. Hollyman, Y. Endo, H. Ye, M.-Q. Du, and C. Boshoff K15 Protein of Kaposi's Sarcoma-Associated Herpesvirus Is Latently Expressed and Binds to HAX-1, a Protein with Antiapoptotic Function J. Virol., January 15, 2002; 76(2): 802 - 816. [Abstract] [Full Text] [PDF] J. An, A. K. Lichtenstein, G. Brent, and M. B. Rettig The Kaposi sarcoma-associated herpesvirus (KSHV) induces cellular interleukin 6 expression: role of the KSHV latency-associated nuclear antigen and the AP1 response element Blood, January 15, 2002; 99(2): 649 - 654. [Abstract] [Full Text] [PDF] S. Pati, M. Cavrois, H.-G. Guo, J. S. Foulke Jr., J. Kim, R. A. Feldman, and M. Reitz Activation of NF-{kappa}B by the Human Herpesvirus 8 Chemokine Receptor ORF74: Evidence for a Paracrine Model of Kaposi's Sarcoma Pathogenesis J. Virol., September 15, 2001; 75(18): 8660 - 8673. [Abstract] [Full Text] [PDF] S. Montaner, A. Sodhi, S. Pece, E. A. Mesri, and J. S. Gutkind The Kaposi's Sarcoma-associated Herpesvirus G Protein-coupled Receptor Promotes Endothelial Cell Survival through the Activation of Akt/Protein Kinase B Cancer Res., March 1, 2001; 61(6): 2641 - 2648. [Abstract] [Full Text] This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Keller, S. A. Articles by Cesarman, E. Search for Related Content PubMed PubMed Citation Articles by Keller, S. A. Articles by Cesarman, E. Related Collections Neoplasia Apoptosis Social Bookmarking                   What's this?

	Copyright © 2000 by American Society of Hematology         Online ISSN: 1528-0020